Anna G Turkina

List of Publications by Year
in descending order

82	1,719	516561 16	289141 40
papers	citations	h-index	g-index

83	83	83	1594
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosomeâ€“positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood, 2011, 118, 4567-4576.	0.6	406
2	Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 7697-7702.	0.8	199
3	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 2021, 138, 2031-2041.	0.6	147
4	Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase. Annals of Internal Medicine, 2018, 168, 461.	2.0	105
5	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24â€month followâ€up. American Journal of Hematology, 2014, 89, 732-742.	2.0	102
6	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood, 2021, 138, 2042-2050.	0.6	95
7	Longâ€term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. American Journal of Hematology, 2015, 90, 755-768.	2.0	72
8	Expanding Nilotinib Access in Clinical Trials (ENACT). Cancer, 2012, 118, 118-126.	2.0	61
9	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia, 2020, 34, 2138-2149.	3.3	55
10	TARGET: a survey of realâ€world management of chronic myeloid leukaemia across 33 countries. British Journal of Haematology, 2020, 190, 869-876.	1.2	40
11	Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leukemia and Lymphoma, 2012, 53, 907-914.	0.6	30
12	Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. Leukemia and Lymphoma, 2018, 59, 733-738.	0.6	29
13	Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, 2018027.	0.5	21
14	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	Article	IF	Citations
19	Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. Blood, 2016, 128, 792-792.	0.6	16
20	National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2020). Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 262-298.	0.1	15
21	PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I. Blood, 2019, 134, 1638-1638.	0.6	15
22	Nilotinib doseâ€optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from <scp>ENEST</scp>xtnd. British Journal of Haematology, 2017, 179, 219-228.	1.2	14
23	Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy. Blood, 2018, 132, 790-790.	0.6	13
24	Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after â‰¥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks. Blood, 2021, 138, 310-310.	0.6	13
25	Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia. BMC Genetics, 2016, 17, 14.	2.7	12
26	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. Blood, 2019, 134, 498-498.	0.6	11
27	Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.. Journal of Clinical Oncology, 2020, 38, 7502-7502.	0.8	11
28	Risks and challenges of CML management during pregnancy: Looking for a balanced decision. European Journal of Haematology, 2019, 102, 378-379.	1.1	10
29	Fluorescence In Situ Hybridization Studies of Interphase Nuclei for Assessing Response to Therapy in Patients with Chronic Myeloid Leukemia. Cancer Genetics and Cytogenetics, 1998, 106, 128-134.	1.0	9
30	Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 267-271.	0.2	9
31	Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 2016, 128, 1891-1891.	0.6	9
32	Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. Blood, 2017, 130, 900-900.	0.6	9
33	The ability of multipotent mesenchymal stromal cells from the bone marrow of patients with leukemia to maintain normal hematopoietic progenitor cells. European Journal of Haematology, 2016, 97, 245-252.	1.1	8
34	Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia. PLoS ONE, 2017, 12, e0182901.	1.1	7
35	Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up. Blood, 2018, 132, 4255-4255.	0.6	6
36	Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy. Blood, 2018, 132, 4254-4254.	0.6	6

#	Article	IF	Citations
37	ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).. Journal of Clinical Oncology, 2019, 37, 7005-7005.	0.8	6
38	PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1T315I. Blood, 2021, 138, 1482-1482.	0.6	6
39	TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ACCORDING TO THE RUSSIAN PART OF THE EUTOS POPULATION-BASED STUDY. Gematologiya I Transfuziologiya, 2019, 64, 106-121.	0.1	5
40	ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S288-S289.	0.2	4
41	Exome, transcriptome and miRNA analysis donâ€™t reveal any molecular markers of TKI efficacy in primary CML patients. BMC Medical Genomics, 2019, 12, 37.	0.7	4
42	Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.. Journal of Clinical Oncology, 2021, 39, 7009-7009.	0.8	4
43	Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. Journal of Clinical Oncology, 2018, 36, 7003-7003.	0.8	4
44	PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy. Blood, 2017, 130, 895-895.	0.6	4
45	ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S222.	0.2	3
46	Factors for Sustaining Molecular Remission after Discontinuation of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia: Results of Non-Randomized Prospective Clinical Trial. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 1-12.	0.1	3
47	ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia. Blood, 2020, 136, 29-30.	0.6	3
48	Treatment-free remission in patients with chronic myeloid leukemia: literature review. Oncogematologiya, 2019, 14, 12-22.	0.1	3
49	Quality of Life of Hematologists in the Russian Federation According to the RAND SF-36 Questionnaire. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 411-419.	0.1	3
50	Dermatologic adverse events of Bcr-Abl tyrosine kinase inhibitors. Gematologiya I Transfuziologiya, 2020, 65, 154-173.	0.1	3
51	A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy. Gematologiya I Transfuziologiya, 2020, 65, 370-385.	0.1	3
52	Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European Journal of Clinical Investigation, 2012, 42, 1016-1026.	1.7	2
53	Treatment of Patients with Chronic Myeloid Leukemia During Pregnancy According to Scheme Considering the Leukemic Burden and Term of Pregnancy (the LRT Scheme). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S227-S228.	0.2	2
54	Diagnosis and Treatment of Clonal Myeloproliferative Neoplasms with Eosinophilia. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 161-169.	0.1	2

#	Article	IF	Citations
55	The First Results of Asciminib Therapy in Highly Pretreated Chronic Myeloid Leukemia Patients Under the Managed Access Program (MAP) in Russian Federation. Blood, 2021, 138, 1483-1483.	0.6	2
56	Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation. Leukemia and Lymphoma, 2018, 59, 2512-2515.	0.6	1
57	Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 118-128.	0.1	1
58	Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI. Blood, 2018, 132, 3023-3023.	0.6	1
59	Clinical features and outcomes in chronic myeloid leukemia with T315I mutation. Cellular Therapy and Transplantation, 2017, 6, 26-35.	0.2	1
60	Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia. Blood, 2018, 132, 1735-1735.	0.6	1
61	CHANGES IN STROMAL PROGENITOR CELLS DERIVED FROM BONE MARROW IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA AT THE ONSET OF THE DISEASE AND DURING TREATMENT. Gematologiya I Transfuziologiya, 2019, 64, 424-435.	0.1	1
62	Humoral Immunity and Adverse Events after Vaccination Against COVID-19 By a Vector Based Vaccine Sputnik V in Patients with Chronic Myeloid Leukemia. Blood, 2021, 138, 4599-4599.	0.6	1
63	Analysis of Mortality of the Multicenter Eutos Eln Population-Based Study (EUTOS-PBS) in Russian Patients with Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S298-S299.	0.2	0
64	Withdrawal Syndrome After Tyrosine Kinase Inhibitors Discontinuation in Patients with Chronic Myeloid Leukemia in Russian Prospective Study (RU-SKI). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S291-S292.	0.2	0
65	CML-083: Prognostic Factors of Durable Treatment-Free Remission in CML Patients Based on the Prospective Study RU-SKI. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S230.	0.2	0
66	CML-143: BCR-ABL1 Translocation Combined with JAK2 or CALR Mutations in Russian CML Patients Undergoing TKI Therapy: Transcript Level and Mutation Allele Burden. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S235-S236.	0.2	0
67	CML-266: Second Generation Tyrosine Kinase Inhibitors in First Line Can Reduce the Time to Treatment-Free Remission in Chronic Myeloid Leukemia Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S239.	0.2	0
68	CML-270: Dose De-Escalation of Second-Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Major and Deep Molecular Response. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S239-S240.	0.2	0
69	Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e328-e335.	0.2	0
70	Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML. Blood, 2016, 128, 5457-5457.	0.6	0
71	Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Blood, 2016, 128, 5437-5437.	0.6	0
72	Analysis of the Effectiveness of Maintenance Therapy By Imatinib in Patients with Pdgfra-Positive Neoplasm. Blood, 2018, 132, 1755-1755.	0.6	0

#	Article	IF	Citations
73	Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study. Blood, 2018, 132, 1740-1740.	0.6	0
74	On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study. Blood, 2019, 134, 5902-5902.	0.6	0
75	The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial. Blood, 2019, 134, 2925-2925.	0.6	0
76	Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment. Blood, 2019, 134, 5014-5014.	0.6	0
77	Frequency of coexistence and kinetics of the BCR-ABL1 transcript level and allele burden of JAK2V617F and CALR Type 1, 2 gene mutations in patients with chronic myeloid leukemia. Gematologiya I Transfuziologiya, 2020, 65, 253-280.	0.1	0
78	Results of a Single Center Survey on Vaccination Against COVID-19 in Patients with Chronic Myeloid Leukemia. Blood, 2021, 138, 4604-4604.	0.6	0
79	The 15 Year Long-Term Survival of Patients with Chronic Myeloid Leukaemia from 35 Regions of Russian Federation: A Follow up of a Multicenter Observation Study Eutos Osp Initiated By European Leukemia NET. Blood, 2021, 138, 5035-5035.	0.6	0
80	Biological Mechanisms of Sustaining Deep Molecular Response in Chronic Myeloid Leukemia Upon Withdrawal of Tyrosine Kinase Inhibitors. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 427-435.	0.1	0
81	The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI. Blood, 2020, 136, 30-31.	0.6	0
82	Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Main Objectives, Design, and Expected Results. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2022, 15, 54-61.	0.1	0